Studies of Multiple Morphine and Enkephalin Receptors: Evidence for Mu1 Receptors

  • Gavril W. Pasternak
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 236)


The concept of receptors plays in integral role in pharmacology. Many drugs act through interactions with specific binding sites and dissociate unchanged, unlike enzymes which modify subtrates. The realization that subtypes of receptors for a ligand may exist has opened a number of possibilities in drug development and remains important. In the past, the classification of receptor subtypes rested heavily upon either classical bioassays or in vivo studies. More recently, the availability of binding assays has permitted a more molecular approach to this question. Both approaches have their advantages and disadvantages. These are important issues since the development of highly selective drugs is often based upon the identification of subtypes of receptors with highly selective functions.


Opioid Peptide Opiate Receptor Morphine Analgesia Delta Receptor High Affinity Component 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Blurton PA, Broadhurst AM, Wood MD, Wyllie MG: Is there a common, high-affinity opioid binding site in rat brain ? J. Receptor Res. 6: 8593, 1986.Google Scholar
  2. Bodnar RJ, Williams CL, Lee SJ, Pasternak GW: Role of mul opiate receptors in supraspinal opiate analgesia. Brain Res., submitted.Google Scholar
  3. Chang K-J, Cooper BR, Hazum e, Cuatrecasas P: Multiple opiate receptors:different regional distribution in the brain and differential binding of opiates and opioid peptides. Mol. Pharmacol. 16: 91–104, 1978.Google Scholar
  4. Chang KJ, Cuatrecasas P: Multiple opiate receptors: enkephalins and morphine bind to receptors of different specificity. J. Biol. Chem. 254: 2610–2618, 1979.Google Scholar
  5. Clark JA, Itzhak Y, Hruby VJ, Yamamura HI, Pasternak GW: [D-Pen2,D-Pen5JEnkephalin (DPDPE): a delta-selective enkephalin with low affinity for µl opiate binding sites. Eur. J. Pharmacol. 128: 303304, 1986.Google Scholar
  6. Clark JA, Pasternak GW: Opiate binding in calf thalamic membranes: I. A selective mul binding assay. Mol. Pharmacol., submitted.Google Scholar
  7. Clark JA, Pasternak GW: U50,488, a kappa-selective agent with poor affinity for mul opiate binding sites. Neuropharmacol., in press.Google Scholar
  8. Cruciani, RA, Lutz RA, Munson PJ, Rodbard D: Naloxonazine effects on the interaction of enkephalin analogs with mu-1, mu and delta opioid binding sites in rat brain membranes. J. Pharmacol. Exp. Ther. 242: 15–20, 1987.Google Scholar
  9. Duka I, Schubert P, Wuster M, Stiber R, Herz A: A selective distribution pattern of different opiate receptors in certain areas of rat brain as revealed by in vitro autoradiography. Neuroscience Letters 21: 119124, 1981.Google Scholar
  10. Frederickson RCA, Smithwick EL, Shuman R, Bemis KG: Metkephamid, a systematically active analog of methionine enkephalin with potent opioid delta receptor activity. Science 211: 603–605, 1981.CrossRefGoogle Scholar
  11. Gintzler AR, Pasternak GW: Multiple mu receptors: Evidence for mut sites in the guinea pig ileum. Neurosci. Lett 39: 51–56, 1983.CrossRefGoogle Scholar
  12. Goodman RR, Pasternak GW: Visualization of mul opiate receptors in rat brain using a computerized autoradiographic subtraction technique. Proc. Nat. Acad. Sci. U.S.A. 82: 6667–6671, 1985.CrossRefGoogle Scholar
  13. Goodman RR, Snyder SH, Kuhar MJ, Young WS: Differentiation of delta and mu opiate receptor localizations by light microscopic autoradiography. Proc. Natl. Acad. Sci. U.S.A. 77: 6239–6243, 1980.CrossRefGoogle Scholar
  14. Hahn EF, Carroll-Buatti M, Pasternak GW: Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphine azines. J. Neurosci 2: 57 2576, 1982.Google Scholar
  15. Hazum E, Chang K-J, Cuatrecasas P, Pasternak GW: Naloxazone irreversiblyinhibits the high affinity binding of (125]I-DAla2-DLeu5-enkephalin. Life Sci. 28: 2973–2979, 1981.CrossRefGoogle Scholar
  16. Heyman JS, Williams CL, Burks TF, Mosberg HI, Porreca F: Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. J. Pharmacol. Exp. Ther., in pressGoogle Scholar
  17. Houde RW, Wallenstein SL: Clinical studies of morphine-nalorphine combination Fed. Proc. 15: 440–441, 1956.Google Scholar
  18. Houghten R, Johnson N, Pasternak GW: 3H-beta-endorphin binding to rat brain membranes. J. Neurosci. 4: 2460–2464, 1984.Google Scholar
  19. Hughes J: Isolation of an endogenous compound from the brain witl. pharmacological properties similar to morphine. Brain Res. 88: 295308, 1975.Google Scholar
  20. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR: Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258: 577–579, 1975.CrossRefGoogle Scholar
  21. Itzhak Y, Pasternak GW: Interaction of [D-Ser2,Leu5]enkephalin-Thr6 (DSLET), a relatively selective delta ligand, with mul opioid binding sites. Life Sci. 40: 307–311, 1987.CrossRefGoogle Scholar
  22. Johnson N, Pasternak GW: Binding of 3H-naloxonazine to rat brain membranes. Mol. Pharmacol 26: 477–483, 1984.Google Scholar
  23. Kosterlitz HW, Paterson SJ: Tyr-D-Ala-Gly-McPhe-NHCOCH2OH is selective ligand for the mu opiate binding sites. Br. J. Pharmacol 73: 299p, 1981.Google Scholar
  24. Ling GSF, Macleod JM, Lee S, Lockhart S, Pasternak GW: Separation of morphine analgesia from physical dependence. Science 226: 462–464, 1984.CrossRefGoogle Scholar
  25. Ling GSF, Pasternak GW: Spinal and supraspinal analgesia in the mouse: the role of subpopulations of opioid binding sites. Brain Res. 271: 152–156, 1983.CrossRefGoogle Scholar
  26. Ling GSF, Simantov R, Clark JA, Pasternak GW: Naloxonazine actions in vivo. Eur. J. Pharmacol. 129: 33–38, 1986.CrossRefGoogle Scholar
  27. Ling GSF, Spiegel K, Lockhart SH, Pasternak GW: Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J. Pharmacol. Exp. Ther. 232: 149–155, 1985.Google Scholar
  28. Ling GSF, Spiegel K, Nishimura S, Pasternak GW: Dissociation of morphine’s analgesic and respiratory depressant actions. Europ. J. Pharmacol. 86: 487–488, 1983.CrossRefGoogle Scholar
  29. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW: Endogenous opioid peptides: multiple agonists and receptors. Nature (London) 267: 495499, 1977.Google Scholar
  30. Lutz RA, Cruciani RA, Munson PJ, Rodbard D: Mul: a very high affinity subtype of enkephalin binding sites in rat brain. Life Sci. 36, 22332338, 1985.Google Scholar
  31. Lutz RA, Cruciani RA, Costa T, Munson PJ, Rodbard D: A very high affinity opioid binding site in rat brain: demonstration by computer modeling. Biochem. Biophys. Res. Comm. 122: 265–269, 1984.CrossRefGoogle Scholar
  32. Martin WR: Opioid antagonists. Pharmacol. Rev. 19: 463–521, 1967.Google Scholar
  33. Martin WR, Eades CG, Thompsoon JA, Huppler RE, Gilbert PE: The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Therap. 197: 517–532, 1976.Google Scholar
  34. Mosberg HI, Hurst R, Hruby VJ, Gee K, Yamamura HI, Galligan JJ, Burks TF: Bispenicillamine enkephalins possess highly improved specificity towards delta opiate receptors. Proc. Natl. Acad. Sci. USA 80: 58715874, 1983.Google Scholar
  35. Moskowitz, A.S. and R.R. Goodman. Autoradiographic distribution of mul and mu2 opioid binding in the mouse central nervous system. Brain Res. 360: 117–129, 1985a.CrossRefGoogle Scholar
  36. Moskowitz, A.S.and R.R. Goodman. Autoradiographic analysis of mul, mu2 and delta opioid binding in the central nervous system of C57BL/6BY and CXBK (opioid recepor deficient) mice. Brain Res. 360: 108–116, 1985b.CrossRefGoogle Scholar
  37. Munson PeterJ, Rodbard David: Ligand: a versatile computerized approach for characterization of ligand-binding systems. Analytical Biochemistry 107: 220–239, 1980.CrossRefGoogle Scholar
  38. Nishimura SL, Recht LD, Pasternak GW: Biochemical characterization of high affinity 3H-opioid binding: furher evidence for mul sites. Mol. Pharmacol. 25: 29–37, 1984.Google Scholar
  39. Pasternak GW: Multiple opiate receptors: [3H]Ethylketocyclazocine receptor binding and ketocyclazocine analgesia. Proc. Natl. Acad. Sci. U.S.A. 77: 3691–3694, 1980.CrossRefGoogle Scholar
  40. Pasternak GW: Opiate, enkephalin and endorphin analgesia: relations to a single subpopulation of opiate receptors. Neurology 31: 1311–1315, 1981.CrossRefGoogle Scholar
  41. Pasternak GW, Childers SR, Snyder SH: Naloxazone, a long-acting opiate antagonist: effects on analgesia in intact animals and on opiate receptor binding in vitro. J. Pharmacol. Exp. Ther. 214: 455–462, 1980.Google Scholar
  42. Pasternak GW, Childers SR, Snyder SH: Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors. Science 208: 514516, 1980.Google Scholar
  43. Pasternak GW, Goodman R, Snyder SH: An endogenous morphine-like factor in mammalian brain. Life Sci. 16: 1765–1769, 1975.CrossRefGoogle Scholar
  44. Pasternak GW, Hahn EF: Long acting opiate agonists and antagonists: 14-hydroxydiphydromorphinone hydrazone. J. Med. Chem. 23: 674–676, 1980.CrossRefGoogle Scholar
  45. Pasternak GW, Snyder SH: Identification of novel high affinity opiate receptor binding in rat brain. Nature 253: 563–565, 1975.CrossRefGoogle Scholar
  46. Porreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF: Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-late analgesia in the mouse. J. Pharmacol. Exp. Ther. 230: 341–348, 1984.Google Scholar
  47. Spiegel K, Kourides I, Pasternak GW: Prolactin and growth hormone release by morphine in the rat: different mechanisms. Science 217: 745–747, 1982.CrossRefGoogle Scholar
  48. Simone DA, Bodnar, RJ, Pasternak, GW: Involvement of opioid receptor subtypes in rat feeding behavior. Life Sci. 36: 829–833, 1985.CrossRefGoogle Scholar
  49. Terenius L, Whalstrom A: Search for an endogenous ligand for the opiate receptor. Acta Physiol. Scand. 94: 74–81, 1975.Google Scholar
  50. Toll L, Keys C, Polgar W, Loew G: The use of computer modeling in describing multiple opiate receptors. Neuropeptides 5: 205–208, 1984.CrossRefGoogle Scholar
  51. Wolozin BL, Pasternak GW: Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc. Nat. Acad. Sci. USA 78: 6181–6185, 1981.CrossRefGoogle Scholar
  52. Wood PL, Pasternak Gw: Specific mut opioid isoreceptor regulation of nigrostriatal neurons: in vivo evidence with naloxonazine. Neurosci. Lett. 37: 291–293, 1983.CrossRefGoogle Scholar
  53. Wood PL, Richard JW, Thakur M: Mu opiate isoreceptors: Differentiation with kappa agonists. Life Sci. 31: 2313–2317, 1982.CrossRefGoogle Scholar
  54. Wood PL, Stotland LM, Richard JW, Rackham A: Actions of mu, kapa, sigma, delta and agonist/antagonist opoiates on striatal dopaminergic function. J. Pharmacol. Exp. Ther. 215: 697–703, 1980.Google Scholar
  55. Yaksh TL: In vivo studies on spinal opiate receptor systems mediating antinociception: I. mu and delta receptor profiles in the primate. J. Pharamcol. Exp. Ther. 1983; 226: 303–316.Google Scholar
  56. Zhang A-Z, Pasternak GW: Opiates and enkephalins: a common binding site mediates their analgesic actions in rats. Life Sciences 29: 843–857, 1981CrossRefGoogle Scholar
  57. Zhang A-Z, Pasternak GW: Mu and delta opiate receptors: correlation with high and low affinity opiate binding sites. Europ. J. Pharmacol. 67: 323–324, 1982.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Gavril W. Pasternak
    • 1
    • 2
  1. 1.The Cotzias Laboratory of Neuro-OncologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Departments of Neurology and PharmacologyCornell U. Medical CollegeNew YorkUSA

Personalised recommendations